Dossier assessment
Belzutifan (Von-Hippel-Lindau disease) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Belzutifan (Von-Hippel-Lindau disease) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Belzutifan (Von-Hippel-Lindau disease) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adult patients with von Hippel-Lindau disease who require therapy for associated localized renal cell carcinoma, central nervous system haemangioblastomas or pancreatic neuroendocrine tumours, and for whom localized procedures are unsuitable
Added benefit not proven
Project details
- Project no.
- A25-44
- Commission
- Commission awarded on 31.03.2025 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A25-44_en
Connected Projects
-
Dossier assessment
Belzutifan (renal cell carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed